PET/MRI monitoring for PD-L1–positive triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This early-phase study uses advanced PET/MRI scans to monitor how immunotherapy treatment works in people with triple-negative breast cancer that is PD-L1 positive. It may help doctors better track tumor changes in the body over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 75 years old.
- You have biopsy-proven triple-negative breast cancer that is stage II to IV.
- Your tumor must be PD-L1 positive (more than 50%).
- You have not started any immunotherapy yet (no prior immunotherapy in before or after surgery).
- You can do multiple scans: you must be able to lie still for about 1 hour and have no MRI contraindications (like certain non-removable metal).
- You must have measurable disease: at least one tumor spot bigger than 1 cm that can be seen on a recent breast MRI or CT scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan (68Ga-FAPI-46) to see if it can predict how well chemotherapy plus immunotherapy (pembrolizumab) works in people with triple-negative breast cancer before surgery. It aims to help doctors understand if the treatment is effective earlier.
This trial uses a special PET scan to see if PSMA, a protein on some cancer cells, can help detect triple-negative breast cancer that has spread to other parts of the body.
This trial tests whether a special PET scan can help guide the best combination of chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. It aims to personalize treatment and improve outcomes.
This early-phase study looks at how well PET/MRI scans can monitor treatment response in people with HER2-positive breast cancer before surgery. You may be asked to undergo specific scans during “neoadjuvant” therapy (treatment given before the main operation).
This study uses special PET and MRI scans to map the activity and oxygen levels of brain tumors (gliomas). The results help doctors plan treatment that is more tailored to each patient.
This study tests whether a new type of PET/MRI scan can help doctors see how well breast cancer treatment is working. It is a platform study, meaning it can evaluate different treatments, but the focus is on using this advanced imaging to monitor response.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.